NCT00496093View on ClinicalTrials.gov

Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011)

PHASE3CompletedINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

January 31, 2006

Study Completion Date

January 31, 2006

Conditions
Pneumococcal Infection
Interventions
BIOLOGICAL

Pneumococcal Vaccine, Polyvalent (23-valent)

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00496093 - Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011) | Biotech Hunter | Biotech Hunter